310 related articles for article (PubMed ID: 27890243)
21. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
[TBL] [Abstract][Full Text] [Related]
22. [Residual risk: The roles of triglycerides and high density lipoproteins].
Grammer T; Kleber M; Silbernagel G; Scharnagl H; März W
Dtsch Med Wochenschr; 2016 Jun; 141(12):870-7. PubMed ID: 27305303
[TBL] [Abstract][Full Text] [Related]
23. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea.
Kim HS; Kim H; Jeong YJ; Yang SJ; Baik SJ; Lee H; Lee SH; Cho JH; Choi IY; Yim HW; Yoon KH
J Clin Pharm Ther; 2016 Oct; 41(5):508-14. PubMed ID: 27426000
[TBL] [Abstract][Full Text] [Related]
25. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
[TBL] [Abstract][Full Text] [Related]
26. [Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
Brath H; Wascher TC; Kästenbauer T; Toplak H
MMW Fortschr Med; 2012 Jun; 154 Suppl 2():41-7. PubMed ID: 23424754
[TBL] [Abstract][Full Text] [Related]
27. Patient characteristics and medical care costs associated with hypertriglyceridemia.
Nichols GA; Arondekar B; Garrison LP
Am J Cardiol; 2011 Jan; 107(2):225-9. PubMed ID: 21211599
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
31. Hypertriglyceridemia and cardiovascular risk reduction.
Jacobson TA; Miller M; Schaefer EJ
Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
[TBL] [Abstract][Full Text] [Related]
32. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients.
Toth PP; Philip S; Hull M; Granowitz C
Mayo Clin Proc; 2019 Sep; 94(9):1670-1680. PubMed ID: 31405751
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events.
McCullough PA; Ahmed AB; Zughaib MT; Glanz ED; Di Loreto MJ
Rev Cardiovasc Med; 2011; 12(4):173-85. PubMed ID: 22249508
[TBL] [Abstract][Full Text] [Related]
34. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics.
Vincenzi B; Borba CP; Gray DA; Copeland PM; Wang X; Fan X; Aragam GG; Henderson DC
Ann Clin Psychiatry; 2013 May; 25(2):141-8. PubMed ID: 23638445
[TBL] [Abstract][Full Text] [Related]
35. Use of combination therapy for dyslipidemia: a lipid clinic approach.
Brown AS
Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias.
Suh HS; Hay JW; Johnson KA; Doctor JN
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):470-84. PubMed ID: 22461130
[TBL] [Abstract][Full Text] [Related]
37. Hypertriglyceridemia: the importance of identifying patients at risk.
Kushner PA; Cobble ME
Postgrad Med; 2016 Nov; 128(8):848-858. PubMed ID: 27710158
[TBL] [Abstract][Full Text] [Related]
38. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
Farnier M
Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
[TBL] [Abstract][Full Text] [Related]
40. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Am J Cardiol; 2016 May; 117(9):1444-8. PubMed ID: 26969416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]